Philip Serlin, BioLineRx CEO

Bi­o­Lin­eRx’s Aphex­da ap­proved to aid stem cell trans­plants for mul­ti­ple myelo­ma pa­tients

Au­tol­o­gous stem cell trans­plan­ta­tion (AS­CT) is part of the stan­dard of care for pa­tients with mul­ti­ple myelo­ma. It’s a process in which a pa­tient’s own stem cells are re­moved and rein­tro­duced, of­ten af­ter treat­ment with chemother­a­py. But some pa­tients don’t make good can­di­dates.

Less than half of pa­tients have had trou­ble col­lect­ing tar­get num­bers of hematopoi­et­ic stem cells in one round, de­pend­ing on oth­er fac­tors, ac­cord­ing to Tel Aviv-based biotech Bi­o­Lin­eRx. The com­pa­ny hopes to change that with its new­ly ap­proved ther­a­py: Aphex­da, al­so known as motix­afor­tide.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.